Dublin-based Alkermes has seen sales of its opioid abuse drug Vivitrol soar in recent years as communities have scrambled for ways to fight opioid addiction and the overdoses that come with it.
Now the drugmaker intends to increase capacity of the drug’s production and add nearly 100 jobs to the Ohio plant that manufactures it.
The expansion will add about $5.3 million in payroll, along with the 90 added jobs, to the Wilmington, Ohio, plant, according to the Ohio Tax Credit Authority, reported the Dayton Business Journal. The authority has granted tax benefits for the project. The drugmaker has also agreed to maintain about 400 already working at the 280,000 square plant. A spokesperson could not be reached Monday.
Vivitrol is manufactured exclusively at the Wilmington plant. Approved 10 years ago, it had little success as a treatment for alcoholism but after being approved to treat opioid abuse, sales of the $1,300-a-month drug have grown significantly, up 53% last year to $144.4 million. The company has yet to report its Q4 or 2016 full-year’s numbers, but in Q3, the company reported net sales of Vivitrol reached $55.8 million, up 47% from sales of $37.9 million in the same quarter of 2015.
Vivitrol is among drugs decided to keep when it made the decision in 2015 to narrow its focus. At the time, it sold a half dozen drugs and a manufacturing plant in Gainesville, Georgia, to Pennsylvania-based Recro Pharma. Recro agreed to pay $50 million in cash and up to $120 million in milestone payments.
By Eric Palmer
Source: Fierce Pharma
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.